Related Experiment Videos
Shared pathways: death receptors and cytotoxic drugs in cancer therapy
1St. Jude Children s Research Hospital, Department of Hematology-Oncology 332 North Lauderdale, Memphis 38105, USA.
Abstract:
Death ligands (TNF, FasL, TRAIL) and their respective death receptor signaling pathways can be used to induce tumor cells to undergo apoptosis. Chemotherapeutic drugs can induce apoptosis and the upregulation of death ligands or their receptors. Downstream events following cytotoxic stress-induced DNA damage and the signaling pathways that lead to the induction of apoptosis may be either dependent or independent of death receptor signaling. The involvement of the Fas signaling pathway in chemotherapy-induced apoptosis has been the most extensively studied, with the current emergence of information on the TRAIL signaling pathway. Fas-mediated and chemotherapy-induced apoptosis can converge at the level of the receptor, FasL, DISC formation, activation of the initiator caspase-8, at the level of the mitochondria, or at the level of downstream effector caspase activation. Convergence is influenced by the specific form of DNA damage, the cellular environment, and the specific pathway(s) by which death receptor-mediated or drug-mediated apoptosis are induced. This review discusses the different levels of interaction between signaling pathways in the different forms of cell death.
Insights
Chemotherapy can trigger tumor cell death (apoptosis) through death receptor pathways like Fas and TRAIL. These pathways can converge with chemotherapy-induced apoptosis at multiple cellular levels, depending on DNA damage and cellular context.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- Death ligands (TNF, FasL, TRAIL) and their receptors mediate apoptosis, a key process for eliminating tumor cells.
- Chemotherapeutic drugs can induce apoptosis and modulate death ligand/receptor expression, impacting treatment efficacy.
- Apoptosis can be triggered by cytotoxic stress and DNA damage, involving pathways that may or may not depend on death receptors.
Purpose of the Study:
- To review the intricate interactions between death receptor signaling pathways and chemotherapy-induced apoptosis.
- To elucidate the convergence points between Fas/TRAIL-mediated apoptosis and drug-induced cell death.
- To discuss how DNA damage, cellular environment, and specific induction pathways influence these interactions.
Main Methods:
- Literature review of studies investigating death receptor signaling and chemotherapy-induced apoptosis.
- Analysis of molecular mechanisms underlying the convergence of these apoptotic pathways.
- Examination of factors influencing the interplay between death receptor-mediated and drug-mediated apoptosis.
Main Results:
- The Fas signaling pathway's role in chemotherapy-induced apoptosis is well-established, with growing evidence for TRAIL signaling.
- Convergence between Fas-mediated and chemotherapy-induced apoptosis occurs at various levels: receptor, DISC, mitochondria, and effector caspases.
- The specific type of DNA damage and cellular context dictate the extent and nature of pathway convergence.
Conclusions:
- Death receptor pathways and chemotherapy can synergistically induce tumor cell apoptosis through complex signaling interactions.
- Understanding these convergence points is crucial for developing novel cancer therapeutic strategies.
- Further research into the fine-tuning of these pathways could lead to more effective and targeted cancer treatments.